11 min listen
Hyped weight loss drugs raise equity concerns
From1 big thing
ratings:
Length:
12 minutes
Released:
Feb 15, 2023
Format:
Podcast episode
Description
In 2022, more than 5 million prescriptions were written for diabetes drugs to be used for weight loss. The demand spiked because of social media influencers and celebrities touting the benefits. But widespread off-label use of diabetes drugs is raising concerns about cost and shortages.
Plus, last week’s earthquake becomes Turkey's deadliest in 100 years.
And, human intervention is keeping manatees alive in Florida – but for how long?
Guests: Axios' Tina Reed and University of Miami's Dr. Jill Richardson.
Credits: Axios Today is produced by Niala Boodhoo, Alexandra Botti, Naomi Shavin, Fonda Mwangi and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893.
Go Deeper:
Hyped weight loss drugs raise supply, equity concerns
Wildlife officials bring back feeding program for Florida manatees
Earthquake becomes Turkey's deadliest in 100 years
Learn more about your ad choices. Visit megaphone.fm/adchoices
Plus, last week’s earthquake becomes Turkey's deadliest in 100 years.
And, human intervention is keeping manatees alive in Florida – but for how long?
Guests: Axios' Tina Reed and University of Miami's Dr. Jill Richardson.
Credits: Axios Today is produced by Niala Boodhoo, Alexandra Botti, Naomi Shavin, Fonda Mwangi and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893.
Go Deeper:
Hyped weight loss drugs raise supply, equity concerns
Wildlife officials bring back feeding program for Florida manatees
Earthquake becomes Turkey's deadliest in 100 years
Learn more about your ad choices. Visit megaphone.fm/adchoices
Released:
Feb 15, 2023
Format:
Podcast episode
Titles in the series (100)
What's next for Trump vs. Biden: What's next for both campaigns, the new stock market traders and inside the Oval Office. by 1 big thing